Phaseline

Targets › PBPB

PBPB: drug programs, companies and trials

5 programs from 3 companies in 6 trials: 3 Phase 4, 3 Phase 3; Infectious disease; next expected readout Dec 2028.

Open in Phaseline: the race on PBPB, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of MelbourneCefazolin
Bacterial penicillin-binding protein inhibitor
PBPBPhase 4Staphylococcus Aureus BacteremiaDec 2028
University of MelbournePenicillin G
Bacterial penicillin-binding protein inhibitor
PBPBPhase 4Staphylococcus Aureus BacteremiaDec 2028
Carilion ClinicCephalexin
Bacterial penicillin-binding protein inhibitor
PBPBPhase 4Surgical Site Infection–
Tampere University HospitalCloxacillin
Penicillin-binding protein inhibitor
PBPBPhase 3InfectionDec 2028
Tampere University HospitalPiperacillin
Bacterial penicillin-binding protein inhibitor
PBPBPhase 3InfectionDec 2028

Conditions

Infection (3) Staphylococcus Aureus Bacteremia (2) Surgical Site Infection (1)

Modalities

small molecule (5)

Companies

University of Melbourne (2) Tampere University Hospital (2) Carilion Clinic (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.